Profitability
This table compares TransEnterix and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TransEnterix | -2,149.15% | -83.74% | -64.94% |
| TransEnterix Competitors | -672.41% | -133.75% | -59.01% |
Earnings & Valuation
This table compares TransEnterix and its competitors top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| TransEnterix | $8.53 million | -$154.20 million | -0.04 |
| TransEnterix Competitors | $59.55 million | -$32.15 million | 4.12 |
TransEnterix’s competitors have higher revenue and earnings than TransEnterix. TransEnterix is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
Volatility and Risk
TransEnterix has a beta of 2.56, meaning that its share price is 156% more volatile than the S&P 500. Comparatively, TransEnterix’s competitors have a beta of 1.76, meaning that their average share price is 76% more volatile than the S&P 500.
Summary
TransEnterix competitors beat TransEnterix on 7 of the 9 factors compared.
About TransEnterix
TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. TransEnterix, Inc. is headquartered in Morrisville, North Carolina.
Receive News & Ratings for TransEnterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransEnterix and related companies with MarketBeat.com's FREE daily email newsletter.
